Physician profile
Stephen J Pandolph
NPI 1053311761
$1,328.81
in general payments reported to CMS, 2019-2025
18 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2022: $45.86 · 2023: $247 · 2024: $238 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.51 | 2019-2025 | |
| Pfizer INC. | $154.72 | 2019-2025 | |
| Novo Nordisk INC | $100.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $98.94 | 2019 | |
| Glaxosmithkline, LLC. | $97.65 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $68.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $54.56 | 2019 | |
| Abbott Laboratories | $47.33 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $43.19 | 2019-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $42.70 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.79 | 2019 | |
| Dexcom, INC. | $39.76 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $33.69 | 2019 | |
| Sumitomo Pharma America, INC. | $25.55 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $23.13 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $19.49 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.57 | 2022 | |
| Sanofi Pasteur INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pandolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.